Yearly Archives: 2014
2015: efficiencies, competitive differentiation and flexibility
As 2014 comes to a close, planning for 2015 begins. For many organisations wanting to establish a presence in the Australian pharmaceutical and medical device market, engaging third party professional services is an important consideration. Engaging third party professional services … Continue reading
One year anniversary at 500 Collins Street
Today Commercial Eyes celebrates one year operating in our office at 500 Collins Street, Melbourne. Our primary objective in moving the Commercial Eyes business to Melbourne’s CBD was to be located in a place that was easily accessible to staff … Continue reading
2015: Through the looking glass
Imagine if 2015 promised to deliver to the Australian health care environment: An easy to navigate and efficient pathway to market; A predictable regulatory and funding environment; Consensus on the value of innovation; Maintenance of intellectual property rights; A discernible … Continue reading
Inside Commercial Eyes: a focus on continuous improvement
Commercial Eyes staff from our Sydney and Melbourne offices will be coming together today for our bi-annual staff development day. This is an excellent opportunity for our newer team members to become acquainted with the larger organisation, for us to … Continue reading
Commercial Eyes – now a comprehensive commercialisation service solution
The addition of Clinical Development to the Commercial Eyes suite of services this year means that we are now better positioned than ever to provide top to tail commercialisation services for drugs and devices entering the Australian and neighbouring marketplaces. … Continue reading
Uncertain, unknown or essentially unknowable?
‘Understanding what is uncertain, what is unknown or what is essentially unknowable, and what to do about it in a reimbursement submission’ – this was the key topic for discussion of the Australian Chapter of the International Society for Pharmacoeconomics … Continue reading
Alternatives to Bioequivalence Trials
Earlier this week, Dr Greg Pearce, one of our senior regulatory consultants, presented at the ARCS Melbourne education seminar. His topic was the science and practical application of in vitro alternatives to conventional bioavailability and bioequivalence (BABE) clinical trials in … Continue reading
Local pharma expertise and know how: why you need it
Entering a new marketplace – whether for a medicine, a cosmetic, a device or a complementary medicine – is challenging, time consuming, expensive and often just difficult. There are stringent regulations to be met, local insights to be grasped, specific … Continue reading
What treatment switching means to the future of clinical trials
More and more frequently, treatment switching is occurring in clinical trials, particularly in the area of oncology. Not surprisingly, patients are demanding to be switched (most commonly) from the control treatment arm of a trial to the experimental treatment or … Continue reading
Avoid Safety Data Exchange Agreements headaches
Safety Data Exchange Agreements (SDEAs) are an integral part of the collaboration we see in the pharmaceutical industry these days. Where multiple companies work together to develop and market drugs and devices, large amounts of information are collected by a sometimes … Continue reading
